Observational studyNeurology(R) neuroimmunology & neuroinflammation2023
Intrathecal CD8
Observational study in Neurology(R) neuroimmunology & neuroinflammation, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 20 citations in OpenAlex.
- CD20+ T follicular helper-like cells drive antigen-specific autoimmunity in bullous pemphigoid.The Journal of clinical investigation · 2026Article
- CXCR3 expression on antigen-experienced B cells is systemically dysregulated in type 1 diabetes.Diabetologia · 2026Article
- Article
- B- and T cell receptor sequencing elucidates characteristics of lymphocyte depletion by ocrelizumab.iScience · 2025Article
- CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion.International journal of molecular sciences · 2025Review
- The Evolution of Anti-CD20 Treatment for Multiple Sclerosis: Optimization of Antibody Characteristics and Function.CNS drugs · 2025Review
- Effects of Anti-CD20 Antibody Therapy on Immune Cell Dynamics in Relapsing-Remitting Multiple Sclerosis.Cells · 2025Article
- Association between CD20European journal of neurology · 2025Article
- A role of CD20Frontiers in immunology · 2025Article
- Modeling lymphocyte subset dynamics after ublituximab therapy in patients with multiple sclerosis: an Italian prospective study.Frontiers in immunology · 2025Article
- Current Knowledge about CD3International journal of molecular sciences · 2024Review
- An angel or a devil? Current view on the role of CD8Journal of translational medicine · 2024Review
- The origin of human CD20Frontiers in immunology · 2024Article
- T lymphopenia in multiple sclerosis patients treated with ofatumumab: Even with consideration for CD3Multiple sclerosis journal - experimental, translational and clinicalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveDespite accumulating evidence of intrathecal inflammation in patients with primary progressive multiple sclerosis (PPMS), immunomodulatory and suppressive treatment strategies have proven unsuccessful. With this study, we investigated the involvement of CD20
methodsThe main outcomes in this observational, case-control study were flow cytometry assessments of blood and CSF CD20
resultsAssessing CD20 DISCUSSION: This study shows an association between intrathecal CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.